Ischemic heart disease decisions — 2025

The veteran's service connection for headaches and obstructive sleep apnea was granted. The veteran's request for higher ratings for PTSD, CAD, and various forms of arthritis, as well as a compensable rating for bilateral hearing loss, were denied. However, the veteran was granted TDIU and an effective date for DEA.

The veteran is granted a 10% disability rating for hypertension but denied service connection for heart disability, right carpal tunnel syndrome, left carpal tunnel syndrome, and right shoulder disability.

The Board remanded the claims for service connection of coronary artery disease and obstructive sleep apnea, secondary to PTSD. The Veteran's contention is that his PTSD caused him to become obese which led to these conditions.

The veteran's claims for earlier effective dates and higher ratings were mostly denied, but the issue of an initial rating in excess of 60 percent for coronary artery disease status post coronary artery bypass surgery was remanded.

The Board denied service connection for several conditions, including hypertension and breast cancer residuals. However, it remanded the claims for uterine leiomyomata (fibroids) and related issues.

The Board remanded the veteran's claim for service connection of a heart disability. The Board will consider all evidence related to the veteran's heart conditions.

The Board granted readjudication for a heart condition, including IHD and congestive heart failure. It remanded the claims for service connection for hypertension and for a heart condition secondary to hypertension.

The Board denied earlier effective dates for service connection of coronary artery disease and diabetes mellitus. It granted a 20 percent rating for diabetic peripheral neuropathy before August 14, 2020, but denied higher ratings. The issue of service connection for hypertension was remanded.

The veteran's claims for increased rating of migraine headaches and service connection for left knee, right knee, right hip, and syncope were denied. The claims for heart condition and bilateral pes planus with plantar fasciitis were remanded.

The Board has determined that the Veteran's ischemic heart disease, a presumptive service-connected disability, contributed substantially or materially to his cause of death. The benefit-of-the-doubt rule is applied in favor of the Appellant.

Service connection for coronary artery disease (CAD) is granted based on in-service exposure to herbicide agents in Vietnam.

The appeal for an earlier effective date for service connection of a heart disability was dismissed because the rating decision was merely implementing a previous Board decision.

The veteran's claims for service connection for autoimmune and cardiovascular disabilities were denied. The claims for lumbar spine, radiculopathy, and bilateral knee disabilities were remanded.

The veteran's claim for special monthly compensation (SMC) based on the need for regular aid and attendance was granted. The claim for service connection for Zenker's diverticulum was remanded due to new evidence.

The veteran's claims for higher disability ratings for CAD and PTSD were denied. The claims for prostatitis and TDIU were remanded.

The appeals for service connection for various heart conditions were dismissed due to the veteran's death.

The Board remanded the veteran's claim for service connection of coronary artery disease, including due to anthrax shots. The decision was based on the need to correct errors and consider new evidence, including the PACT Act.

The veteran's claims for an earlier effective date for shin splints were denied. Service connection for tinnitus and headaches was granted, while claims for coronary artery disease and diverticulitis were remanded.

The Board dismissed claims for higher ratings for diabetic peripheral neuropathy and denied higher ratings for several other conditions. It remanded decisions on TDIU and an effective date for Dependents' Educational Assistance.

The veteran's appeal for a higher rating for service-connected coronary artery disease (CAD) was granted. The Board assigned an initial 60 percent rating effective February 13, 2023.